Medical Devices
Medtronic Neuromodulation SynchroMed EL, SynchroMed II and IsoMed Implantable Infusion Pumps
Class 1 Recall
|
Date Recall
Initiated: |
January 16, 2008 |
|---|---|
|
Product:
|
Medtronic Neuromodulation Implantable Infusion Pumps:
The implantable components of the infusion systems listed above include the pump, a side catheter access port, catheters, and/or catheter accessories. |
|
Use:
|
These devices administer drugs to a specific site in the body to treat pain, spasticity (continuous muscle contraction), and cancer. The pump is implanted in the patient, either with or without a side catheter access port, catheters, and catheter accessories. |
|
Recalling Firm:
|
Medtronic Neuromodulation 800 53rd Avenue NE Minneapolis, Minnesota 55440-1250 |
|
Reason for Recall:
|
The company updated the labeling for the devices to include current patient management and treatment recommendations. The company also received reports of inflammatory mass formations at or near the distal tip of intrathecal catheters which infuse opioids, baclofen, or chemotherapy drugs into patients. For more detailed information, see the nearby links. |
|
Public Contact:
|
Patients or customers may contact Medtronic Neuromodulation at 1-800-707-0933 from Monday - Friday, 7:00 a.m. – 6:00 p.m. (Central Standard Time). Use the nearby link to see how to contact Medtronic. |
|
FDA District:
|
Minneapolis |
|
FDA Comments:
|
On January 16, 2008, Medtronic sent a letter to doctors who implant these devices and/or provide care to patients with the implanted device. The letter described the problem, patient risks, patient management, recommendations and next steps. For more information about this recall, including Medtronic's letter to physicians, please see the company’s press release in the nearby links. Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of the product will cause serious injury or death. Health care professionals and consumers may report adverse reactions or quality problems experienced with the use of this product to the FDA's MedWatch Adverse Event Reporting program. See the nearby links to MedWatch. |


